• Overview page

  • Jeff Leyton PhD

  • Endosome escape-Nuclear transport

  • Nuclear active cytotoxin payloads

  • Targeting the 'undruggable'

  • Wolfpack approach

  • Molecular Imaging

  • Team and Location

  • Community impact

  • Education-Protocols

  • Collaborators

  • Blog

  • More

    Use tab to navigate through the menu items.
    • Antibody drug conjugates (8) 8 posts
    • COVID-19 (11) 11 posts
    50% of the top 10 drug launches since 2017 are antibodies!

    50% of the top 10 drug launches since 2017 are antibodies!

    Just another indication of how antibodies will soon dominate the pharmaceutical market https://www.fiercepharma.com/special-report/top-10...
    Roche’s Kadcyla wins NICE backing in early breast cancer use

    Roche’s Kadcyla wins NICE backing in early breast cancer use

    The antibody-drug conjugate Kadcyla that targets HER2-positive cancer did not have any problems with England's National Health Service...
    Immunomedics Announces Pricing of Public Offering of Common Stock

    Immunomedics Announces Pricing of Public Offering of Common Stock

    As I recently posted, Immunomedics had a horrible 2019 with the rejection of their ADC. But 2020 is looking real good. There is no doubt...
    7th ADC approved!

    7th ADC approved!

    Immunomedics finally did it!!!! 2019 was a record year with 3 novel ADCs approved. There was a lot of failures since the last ADC...
    An antibody-drug conjugate carrying a microtubule inhibitor and a DNA alkylator exterts both mechani

    An antibody-drug conjugate carrying a microtubule inhibitor and a DNA alkylator exterts both mechani

    I have often wondered how come I don't see an ADC conjugated to two warheads with unique mechanisms of action? At this years AACR meeting...

    A novel engineered antibody fragment ADC that is not dependent on intracellular degradation for drug

    In this article titled "Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumor activity in mice" the...

    First ever randomized study comparing an ADC to standard of care in platinum-resistant ovarian cance

    In a study sponsored by Genentech titled Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (LIFA) compared to pegylated liposomal...

    March 2017 - Latest news with potential next approved ADC Sacituzumab Govitecan - Triple negative br

    Hello! This months posting I hope you will find interesting because its about Sacituzumab Govitecan (SG) and its impressive clinical...